Education
About Us
Working with TipRanks
Follow Us
PILA PHARMA AB (DE:5KC)
FRANKFURT:5KC
5KC Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.16 - €0.65
Previous CloseN/A
Volume2.28K
Average Volume (3M)17.00
Market Cap
€7.85M
Enterprise Value€90.58M
Total Cash (Recent Filing)kr11.74M
Total Debt (Recent Filing)kr500.00K
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding27,126,623
10 Day Avg. Volume0
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)21.55
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
5KC FAQ
What was PILA PHARMA AB’s price range in the past 12 months?
PILA PHARMA AB lowest stock price was €0.15 and its highest was €0.65 in the past 12 months.
What is PILA PHARMA AB’s market cap?
PILA PHARMA AB’s market cap is €7.85M.
When is PILA PHARMA AB’s upcoming earnings report date?
PILA PHARMA AB’s upcoming earnings report date is Aug 27, 2025 which is in 121 days.
How were PILA PHARMA AB’s earnings last quarter?
Currently, no data Available
Is PILA PHARMA AB overvalued?
According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued.
Does PILA PHARMA AB pay dividends?
PILA PHARMA AB does not currently pay dividends.
What is PILA PHARMA AB’s EPS estimate?
PILA PHARMA AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PILA PHARMA AB have?
PILA PHARMA AB has 27,126,623 shares outstanding.
What happened to PILA PHARMA AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PILA PHARMA AB?
Currently, no hedge funds are holding shares in DE:5KC
---
Company Description
PILA PHARMA AB
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
---
Technical Analysis
Biosergen AB
―
OncoZenge AB
―
Biovica International AB Class B
―
Active Biotech AB
―
Spago Nanomedical AB
―
---